...
首页> 外文期刊>International Journal of Pharmaceutics >Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers
【24h】

Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers

机译:开发用于筛选配方成分和评估纳米结构脂质载体常见质量问题的方案

获取原文
获取原文并翻译 | 示例
           

摘要

The present study investigates the screening of the formulation components as well as evaluates the quality issues of the nanostructured lipid carriers (NLCs) for the anticancer agent, CPT-11. The stepwise screening of the components for the preparation of NLCs requires the selection of liquid lipid or oil, based on the relative solubility of CPT-11 in different oils. Maximum solubility of the CPT-11 was found in capmul MCM-C8 (81 ± 0.5 mg/ml). Hence, it was selected as the liquid lipid for the development of NLCs. Solid lipids gelucire 39/1, glyceryl mono stearate (GSM) and compritol ATO 888 were observed to have good affinity for the drug on systematic screening of different solid lipids. However, gelucire 39/1 and GSM were found to have lower physical compatibility (miscibility) with capmul MCM C-8. Hence, compritol ATO 888 was selected as the solid lipid phase for the preparation of NLCs. Ratio of liquid lipid (oil) to solid lipid was optimized with the intention of maximizing the oil concentration (as oil was found to have higher solubility of drug) as well as producing a lipid mix with sufficient melting point to maintain solid state. The liquid-solid lipid mixture in the ratio up to 30:70 was observed to have sufficient melting point (52.48 ± 1.2 C). Pluronic F-68 was selected as the main surfactant for the preparation of NLCs because of its good emulsification efficacy for the solid lipid liquid mix. The optimized formulation was also evaluated for the different quality issues. PXRD data revealed that the characteristic peaks of the compritol were present in the NLC samples and there was no appreciable polymorphic change when the formulation was stored for 6 months. Electron microscopic and DLS studies proved the absence of different colloidal species. Thermal analysis by DSC revealed that the lipid particles maintained sufficiently good melting point even after nanosizing. Absence of gelation on multiple syringing and resilience for the stress provided by autoclaving further established the quality of the developed NLCs.
机译:本研究调查了制剂成分的筛选,并评估了抗癌剂CPT-11的纳米结构脂质载体(NLC)的质量问题。根据CPT-11在不同油中的相对溶解度,逐步筛选用于制备NLC的成分需要选择液体脂质或油。在capmul MCM-C8中发现了CPT-11的最大溶解度(81±0.5 mg / ml)。因此,它被选作开发NLC的液体脂质。在系统筛选不同的固体脂质时,观察到固体脂质胶凝剂39/1,甘油单硬脂酸酯(GSM)和compritol ATO 888对药物具有良好的亲和力。但是,发现胶粉39/1和GSM与capmul MCM C-8的物理相容性(混溶性)较低。因此,选择compritol ATO 888作为制备NLC的固体脂质相。优化液体脂质(油)与固体脂质的比例,旨在最大化油的浓度(因为发现油具有较高的药物溶解度),并生产具有足够熔点的脂质混合物以保持固态。观察到比例高达30:70的液固脂质混合物具有足够的熔点(52.48±1.2 C)。选择Pluronic F-68作为制备NLC的主要表面活性剂,因为它对固体脂质液体混合物具有良好的乳化功效。还针对不同质量问题评估了优化配方。 PXRD数据显示,在NLC样品中存在compritol的特征峰,当制剂保存6个月时,没有明显的多态性变化。电子显微镜和DLS研究证明不存在不同的胶体物种。通过DSC的热分析表明,即使在纳米尺寸化之后,脂质颗粒也保持足够好的熔点。缺少针对多次注射的胶凝作用和对高压灭菌处理所产生的应力的弹性,进一步确定了已开发NLC的质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号